Samuel M Rubinstein
Overview
Explore the profile of Samuel M Rubinstein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
1944
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jensen C, Deal A, Srikanth S, Nyrop K, Mitin N, LeBlanc M, et al.
J Geriatr Oncol
. 2024 Dec;
:102174.
PMID: 39706780
No abstract available.
2.
Lee K, Paek H, Huang L, Hilton C, Datta S, Higashi J, et al.
Inform Med Unlocked
. 2024 Nov;
50.
PMID: 39493413
Background: Initial insights into oncology clinical trial outcomes are often gleaned manually from conference abstracts. We aimed to develop an automated system to extract safety and efficacy information from study...
3.
Caceres-Nazario B, Rivenbark J, Saha M, Mathews S, Rubinstein S
Ann Hematol
. 2024 Oct;
PMID: 39417832
VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) is an increasingly recognized disorder that occurs due to somatic mutations of a ubiquitin-activating enzyme encoded by ubiquitin-like modifier activating enzyme 1...
4.
Sigworth E, Rubinstein S, Warner J, Chen Y, Chen Q
Ann Appl Stat
. 2024 Aug;
17(4):2993-3012.
PMID: 39104542
In clinical practice medications are often interchanged in treatment protocols when a patient negatively reacts to their first line of therapy. Although switching between medications is common, clinicians often lack...
5.
Tantawy M, Langaee T, Wang D, Rubinstein S, Cornell R, Lenihan D, et al.
Int J Mol Sci
. 2024 Jul;
25(14).
PMID: 39063038
This study investigates the association between circulating microRNA (miRNA) expression and cardiovascular adverse events (CVAE) in multiple myeloma (MM) patients treated with a carfilzomib (CFZ)-based regimen. A cohort of 60...
6.
Mohyuddin G, Rubinstein S, Kumar S, Rajkumar S, Fonseca R, Abdallah N, et al.
Blood Cancer J
. 2024 Jun;
14(1):95.
PMID: 38862493
No abstract available.
7.
Lee K, Paek H, Huang L, Hilton C, Datta S, Higashi J, et al.
medRxiv
. 2024 May;
PMID: 38798420
Background: Initial insights into oncology clinical trial outcomes are often gleaned manually from conference abstracts. We aimed to develop an automated system to extract safety and efficacy information from study...
8.
Shabnaz S, Nguyen T, Williams R, Rubinstein S, Garrett T, Tantawy M, et al.
Clin Transl Sci
. 2024 May;
17(5):e13828.
PMID: 38783568
As a treatment for relapsed or refractory multiple myeloma (MM), carfilzomib has been associated with a significant risk of cardiovascular adverse events (CVAE). The goals of our study were to...
9.
LeBlanc M, Zhou X, Baggett C, Tuchman S, Jensen C, Lichtman E, et al.
Clin Lymphoma Myeloma Leuk
. 2024 May;
24(9):611-620.
PMID: 38760283
Introduction: The therapeutic landscape in relapsed/refractory multiple myeloma (RRMM) has changed rapidly, with twenty-two drug approvals since 2012. We characterized population-level trends in RRMM therapy selection, survival and cost outcomes...
10.
Jensen C, Deal A, Nyrop K, Logan M, Mangieri N, Strayhorn M, et al.
J Geriatr Oncol
. 2023 Dec;
15(2):101680.
PMID: 38104482
Introduction: Geriatric assessment (GA)-guided supportive care programs have been successful in improving treatment outcomes for older adults with solid-organ cancers. This study aimed to evaluate the feasibility of a GA-guided...